Abstract:Purpose/Objective(s) Efficacy of immune checkpoint inhibitors (ICI) in curative head and neck squamous cell carcinoma (HNSCC) may be hampered by therapeutic ablation of tumor-draining lymphatics with standard chemoradiation (CRT). Recent emergence of neoadjuvant immunotherapy in HNSCC highlights the need for biomarkers to optimize anti-tumor immunity while eliminating locoregional microscopic disease. An elevated neutrophil-to-lymphocyte ratio (NLR) may reflect an unfavorable balance between pro-tumor inflammation and anti-tumor immunity and is associated with poor immunotherapy outcomes, yet its role as a biomarker of neoadjuvant HNSCC immunotherapy is unknown. We studied the association between NLR dynamics and prognosis in HNSCC patients treated with neoadjuvant immuno-chemotherapy followed by dose and volume response-stratified CRT. Materials/Methods 106 (71 HPV positive and 35 HPV negative) locoregionally advanced HNSCC patients prospectively enrolled in two clinical trials (NCT03107182; NCT039449150) were treated with neoadjuvant nivolumab and chemotherapy followed by dose and volume response-stratified treatment with reduced or standard CRT (including elimination of elective nodal radiation). NLRs for each patient were calculated at baseline, after neoadjuvant therapy, and 1, 3, 6, 9, and 12 months after treatment completion. NLRs at baseline and after neoadjuvant therapy were divided into quartiles, with high NLRs being the highest quartile (>3.66 and >5.63, respectively). NLR differences between reduced and standard CRT groups were analyzed by Wilcoxon ranked sum test. Overall survival (OS) and progression free survival (PFS) were analyzed by Kaplan-Meier and Cox regression methods. Results Among HPV positive patients, 37% were Stage II/III; among HPV negative patients, 97% were Stage IV (AJCC 8th ed.). 77% of all patients received reduced CRT. Median follow-up was 26.7 months. High NLRs after neoadjuvant nivolumab/chemotherapy were associated with worse OS and PFS (p=0.006 and p=0.03, respectively), while baseline high NLRs demonstrated a non-significant trend toward worse OS and PFS (p=0.16 and p=0.10, respectively). In multivariate analysis controlling for tobacco use, ECOG, stage/HPV status, treatment stratification, and PD-L1 CPS, high NLRs after neoadjuvant nivolumab/chemotherapy remained independently associated with worse OS (HR: 5.58, 95% CI: 1.51-20.56, p=0.01) and PFS (HR: 3.09, 95% CI: 1.10-8.67, p=0.03). During follow-up, NLRs were significantly lower in patients receiving reduced CRT compared to those receiving standard CRT at all time points after treatment (p<0.05). Conclusion High NLRs after neoadjuvant immuno-chemotherapy associated with worse survival in locoregionally advanced HNSCC patients. Reduced CRT led to more favorable NLRs which may enhance anti-tumor immunity after neoadjuvant immunotherapy. Further work characterizing dynamic changes in immune phenotype with neoadjuvant HNSCC immunotherapy is warranted.

Higher aorta dose increased neutrophil-to-lymphocyte ratio resulting in poorer outcomes in stage II-III non-small cell lung cancer

Neutrophil-lymphocyte Ratio As a Prognostic Factor for Stereotactic Body Radiotherapy Treatment of Metastatic Liver Tumors.

[Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].

Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy

Neutrophil-lymphocyte Ratio and Platelet-Lymphocyte Ratio Associations with Heart and Body Dose and Their Effects on Patient Outcomes in Locally Advanced Non-Small Cell Lung Cancer Treated with Definitive Radiotherapy.

Neutrophil to Lymphocyte Ratio As a Prognostic Indicator for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective Study.

Preoperative neutrophil-to-lymphocyte predicts the prognosis of stage I non-small cell lung cancer

Association of Preoperative Neutrophil-to-Lymphocyte Ratio with Clinicopathological Characteristics and Prognosis in Stage I Non-small Cell Lung Cancer

Pretreatment Neutrophil-to-Lymphocyte Ratio Associated with Tumor Recurrence and Survival in Patients Achieving a Pathological Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer

Pretreatment Neutrophil to Lymphocyte Ratio is Associated with Response to Therapy and Prognosis of Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy

A Single Center Retrospective Study Assessing the Prognostic Significance of Pre-Treatment Neutrophil/lymphocyte Ratio in Locally Advanced Nasopharyngeal Carcinoma

Prognostic implications of neutrophil‐to‐lymphocyte ratio in patients with extensive‐stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real‐world study

Prognostic Role of Pretreatment Neutrophil-to-lymphocyte Ratio in Non-Small Cell Lung Cancer Patients Treated with Systemic Therapy: a Meta-Analysis.

Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation

Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Non-small-cell Lung Cancer Treated with Trimodality Therapy

Elevated Neutrophil-to-Lymphocyte Ratio is Associated with Poor Outcomes for Melanoma Patients Treated with PD-1 Inhibitor or Chemotherapy in a Chinese Population.

NLR As a Prognostic Factor in Solid Tumors and in a Transplantable Solid Tumor Mouse Model

Neutrophil-to-Lymphocyte Ratio Kinetics and Survival with Neoadjuvant Immuno-chemotherapy and Response-Stratified Chemoradiation in Locoregionally Advanced Head and Neck Cancer

Predictive Significance of Lymphocyte Level and Neutrophil‐to‐lymphocyte Ratio Values During Radiotherapy in Cervical Cancer Treatment

Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR-TKIs: A Systematic Review and Meta-Analysis

Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients.